Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Dermatology

Free Subscription Articles published in Lancet Retrieve available abstracts of 57 articles: HTML format

Single Articles

September 2025
1. GOLD LS, Armstrong AW, Bissonnette R, Magnolo N, et al
   Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials.
   Lancet. 2025 Sep 18:S0140-6736(25)01576-4. doi: 10.1016/S0140-6736(25)01576.
   PubMed     Abstract available
   
   
   
2. PUIG L
   Icotrokinra in psoriasis: IL-23 receptor antagonism via oral peptide with biologic-level efficacy.
   Lancet. 2025 Sep 18:S0140-6736(25)01675-7. doi: 10.1016/S0140-6736(25)01675.
   PubMed    
   
   
   August 2025
3. 
   Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy.
   Lancet. 2025;406:603-614.
   PubMed     Abstract available
   
   
   
4. BRAIN E, Mir O, Bourbouloux E, Rigal O, et al
   Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial.
   Lancet. 2025;406:489-500.
   PubMed     Abstract available
   
   
   July 2025
5. TANG JY, Marinkovich MP, Wiss K, McCarthy D, et al
   Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial.
   Lancet. 2025;406:163-173.
   PubMed     Abstract available
   
   
   June 2025
6. EBENS CL
   Targeting challenging RDEB skin wounds with gene therapy.
   Lancet. 2025 Jun 23:S0140-6736(25)01154-7. doi: 10.1016/S0140-6736(25)01154.
   PubMed    
   
   
   May 2025
7. GILBERT FJ, Payne NR, Allajbeu I, Yit L, et al
   Comparison of supplemental breast cancer imaging techniques-interim results from the BRAID randomised controlled trial.
   Lancet. 2025 May 21:S0140-6736(25)00582-3. doi: 10.1016/S0140-6736(25)00582.
   PubMed     Abstract available
   
   
   
8. GIMENEZ-ARNAU AM, Pinter A, Sondermann W, Reguiai Z, et al
   Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial.
   Lancet. 2025;405:1676-1688.
   PubMed     Abstract available
   
   
   February 2025
9. GUTTMAN-YASSKY E, Renert-Yuval Y, Brunner PM
   Atopic dermatitis.
   Lancet. 2025;405:583-596.
   PubMed     Abstract available
   
   
   
10. DUNN JA, Donnelly P, Elbeltagi N, Marshall A, et al
    Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial.
    Lancet. 2025;405:396-407.
    PubMed     Abstract available
    
    
    
11. SABAT R, Alavi A, Wolk K, Wortsman X, et al
    Hidradenitis suppurativa.
    Lancet. 2025;405:420-438.
    PubMed     Abstract available
    
    
    January 2025
12. FIORENTINO D, Mangold AR, Werth VP, Christopher-Stine L, et al
    Efficacy, safety, and target engagement of dazukibart, an IFNbeta specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
    Lancet. 2025;405:137-146.
    PubMed     Abstract available
    
    
    December 2024
13. WEIDINGER S, Novak N
    Hand eczema.
    Lancet. 2024;404:2476-2486.
    PubMed     Abstract available
    
    
    November 2024
14. CHONG DHY, Pasternak S, Taylor T, Armstrong S, et al
    Skin biopsy findings of dyskeratotic keratinocytes and vacuolar interface change in a patient with Still's disease.
    Lancet. 2024;404:e6.
    PubMed    
    
    
    
15. SOMA T, Oie Y, Takayanagi H, Matsubara S, et al
    Induced pluripotent stem-cell-derived corneal epithelium for transplant surgery: a single-arm, open-label, first-in-human interventional study in Japan.
    Lancet. 2024 Nov 7:S0140-6736(24)01764-1. doi: 10.1016/S0140-6736(24)01764.
    PubMed     Abstract available
    
    
    October 2024
16. JAIRATH V, Acosta Felquer ML, Jaihyun Cho R
    IL-23 inhibition for chronic inflammatory disease.
    Lancet. 2024;404:1679-1692.
    PubMed     Abstract available
    
    
    
17. 
    Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155 746 women in 151 trials.
    Lancet. 2024;404:1407-1418.
    PubMed     Abstract available
    
    
    
18. TARANTINO P, Tolaney SM
    Progress in breast cancer management.
    Lancet. 2024;404:1376-1378.
    PubMed    
    
    
    September 2024
19. NARAGHI K, Marzo-Ortega H
    Progressive cervical osteophytosis and dysphagia associated with isotretinoin treatment for rosacea.
    Lancet. 2024;404:e4.
    PubMed    
    
    
    August 2024
20. LEBWOHL MG, Thoma C, Haeufel T
    Spesolimab use in generalised pustular psoriasis flares - Authors' reply.
    Lancet. 2024;404:847-848.
    PubMed    
    
    
    
21. OSBORNE S, Thacker S, Kam O, Wescott R, et al
    Spesolimab use in generalised pustular psoriasis flares.
    Lancet. 2024;404:846-847.
    PubMed    
    
    
    
22. MANN GB, Rose AK, Zdenkowski N
    Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial - Authors' reply.
    Lancet. 2024;404:526.
    PubMed    
    
    
    
23. KUNKLER I, Cameron D, Dixon M, Williams L, et al
    Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial.
    Lancet. 2024;404:525.
    PubMed    
    
    
    
24. SWANICK CW, Kelly P, Dvorak T, Mamounas EP, et al
    Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial.
    Lancet. 2024;404:525-526.
    PubMed    
    
    
    
25. MO DC, Huang JF, Luo PH, Wang HL, et al
    Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial.
    Lancet. 2024;404:524-525.
    PubMed    
    
    
    
26. RENERT-YUVAL Y, Guttman-Yassky E
    Hands-on: a novel JAK inhibitor for the treatment of chronic hand eczema.
    Lancet. 2024;404:409-411.
    PubMed    
    
    
    July 2024
27. RUGO HS, Bardia A, Tolaney S
    Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial - Authors' reply.
    Lancet. 2024;404:339-340.
    PubMed    
    
    
    
28. HARADA K, Ozaki A, Tanimoto T
    Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
    Lancet. 2024;404:339.
    PubMed    
    
    
    
29. MESSORI A
    Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
    Lancet. 2024;404:338-339.
    PubMed    
    
    
    
30. GU Y
    Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
    Lancet. 2024;404:338.
    PubMed    
    
    
    
31. ERGUN Y
    Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
    Lancet. 2024;404:337-338.
    PubMed    
    
    
    
32. ZUBERBIER T, Ensina LF, Gimenez-Arnau A, Grattan C, et al
    Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment.
    Lancet. 2024;404:393-404.
    PubMed     Abstract available
    
    
    
33. BRUNNER PM
    A novel treatment approach for atopic dermatitis.
    Lancet. 2024 Jul 25:S0140-6736(24)01488-0. doi: 10.1016/S0140-6736(24)01488.
    PubMed    
    
    
    
34. SILVERBERG JI, Wollenberg A, Reich A, Thaci D, et al
    Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials.
    Lancet. 2024 Jul 24:S0140-6736(24)01203-0. doi: 10.1016/S0140-6736(24)01203.
    PubMed     Abstract available
    
    
    
35. BISSONNETTE R, Warren RB, Pinter A, Agner T, et al
    Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials.
    Lancet. 2024 Jul 18:S0140-6736(24)01027-4. doi: 10.1016/S0140-6736(24)01027.
    PubMed     Abstract available
    
    
    June 2024
36. DELALOGE S, Khan SA, Wesseling J, Whelan T, et al
    Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment.
    Lancet. 2024;403:2734-2746.
    PubMed     Abstract available
    
    
    
37. MOLINELLI E, Simonetti O
    Bimekizumab: dual inhibition as a promising tool in the management of hidradenitis suppurativa.
    Lancet. 2024;403:2457-2459.
    PubMed    
    
    
    May 2024
38. BHUTTA MF, Leach AJ, Brennan-Jones CG
    Chronic suppurative otitis media.
    Lancet. 2024;403:2339-2348.
    PubMed     Abstract available
    
    
    
39. KIMBALL AB, Jemec GBE, Sayed CJ, Kirby JS, et al
    Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
    Lancet. 2024 May 22:S0140-6736(24)00101-6. doi: 10.1016/S0140-6736(24)00101.
    PubMed     Abstract available
    
    
    
40. PRASAD A
    Miriam Mutebi: transforming breast cancer care in Africa.
    Lancet. 2024;403:1975.
    PubMed    
    
    
    
41. COLES CE, Haviland JS, Kirby AM, Griffin C, et al
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial - Authors' reply.
    Lancet. 2024;403:1752.
    PubMed    
    
    
    
42. GREGUCCI F, Ciabattoni A
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1751-1752.
    PubMed    
    
    
    
43. MULLIEZ T, De Ridder M
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1751.
    PubMed    
    
    
    
44. GUINOT JL, Gutierrez C, Hannoun-Levi JM
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1750-1751.
    PubMed    
    
    
    
45. MIZUMOTO M, Oshiro Y, Sakurai H
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1749-1750.
    PubMed    
    
    
    
46. ZHAO D, Li Y, Qu Y, He C, et al
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1749.
    PubMed    
    
    
    April 2024
47. DE SOUZA IC, Langer FW
    Post-radiation angiosarcoma of the breast in a patient with a history of invasive ductal carcinoma.
    Lancet. 2024;403:1681-1682.
    PubMed    
    
    
    
48. MOODLEY J, Unger-Saldana K
    The role of racial and ethnic discrimination in breast cancer disparities.
    Lancet. 2024 Apr 12:S0140-6736(24)00699-8. doi: 10.1016/S0140-6736(24)00699.
    PubMed    
    
    
    
49. COLES CE, Earl H, Anderson BO, Barrios CH, et al
    The Lancet Breast Cancer Commission.
    Lancet. 2024 Apr 12:S0140-6736(24)00747-5. doi: 10.1016/S0140-6736(24)00747.
    PubMed    
    
    
    
50. SAMARASEKERA U
    Charlotte Coles: collaborating to tackle breast cancer inequities.
    Lancet. 2024 Apr 12:S0140-6736(24)00752-9. doi: 10.1016/S0140-6736(24)00752.
    PubMed    
    
    
    
51. EARL HM
    Safe de-escalation of chemotherapy in HER2-positive early breast cancer.
    Lancet. 2024 Apr 3:S0140-6736(24)00535-X. doi: 10.1016/S0140-6736(24)00535.
    PubMed    
    
    
    
52. PEREZ-GARCIA JM, Cortes J, Ruiz-Borrego M, Colleoni M, et al
    3-year invasive disease-free survival with chemotherapy de-escalation using an (18)F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
    Lancet. 2024 Apr 3:S0140-6736(24)00054-0. doi: 10.1016/S0140-6736(24)00054.
    PubMed     Abstract available
    
    
    March 2024
53. BRAYBROOKE J, Bradley R, Gray R, Hills R, et al
    Benefits and risks of anthracyclines in early-stage breast cancer - Authors' reply.
    Lancet. 2024;403:1240.
    PubMed    
    
    
    
54. KUDE DE ALMEIDA F, Soares Falcetta F, Dornelles Rosa D
    Benefits and risks of anthracyclines in early-stage breast cancer.
    Lancet. 2024;403:1239-1240.
    PubMed    
    
    
    
55. EMMI G, Bettiol A, Hatemi G, Prisco D, et al
    Behcet's syndrome.
    Lancet. 2024;403:1093-1108.
    PubMed     Abstract available
    
    
    
56. HICKEY M, Basu P, Sassarini J, Stegmann ME, et al
    Managing menopause after cancer.
    Lancet. 2024;403:984-996.
    PubMed     Abstract available
    
    
    February 2024
57. STONE GW, Christiansen EH, Ali ZA, Andreasen LN, et al
    Intravascular imaging-guided coronary drug-eluting stent implantation: an updated network meta-analysis.
    Lancet. 2024 Feb 21:S0140-6736(23)02454-6. doi: 10.1016/S0140-6736(23)02454.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Dermatology is free of charge.